Literature DB >> 7565548

Chorionic villus sampling and amniocentesis: recommendations for prenatal counseling. Centers for Disease Control and Prevention.

.   

Abstract

Chorionic villus sampling (CVS) and amniocentesis are prenatal diagnostic procedures that are performed to detect fetal abnormalities. In 1991, concerns about the relative safety of these procedures arose after reports were published that described a possible association between CVS and birth defects in infants. Subsequent studies support the hypothesis that CVS can cause transverse limb deficiencies. Following CVS, rates of these defects, estimated to be 0.03%-0.10% (1/3,000-1/1,000), generally have been increased over background rates. Rates and severity of limb deficiencies are associated with the timing of CVS; most of the birth defects reported after procedures that were performed at > or = 70 days' gestation were limited to the fingers or toes. The risk for either digital or limb deficiency after CVS is only one of several important factors that must be considered in making complex and personal decisions about prenatal testing. For example, CVS is generally done earlier in pregnancy than amniocentesis and is particularly advantageous for detecting certain genetic conditions. Another important factor is the risk for miscarriage, which has been attributed to 0.5%-1.0% of CVS procedures and 0.25%-0.50% of amniocentesis procedures. Prospective parents considering the use of either CVS or amniocentesis should be counseled about the benefits and risks of these procedures. The counselor should also discuss both the mother's and father's risk(s) for transmitting genetic abnormalities to the fetus.

Entities:  

Mesh:

Year:  1995        PMID: 7565548

Source DB:  PubMed          Journal:  MMWR Recomm Rep        ISSN: 1057-5987


  7 in total

1.  Prenatal diagnosis of sickle cell disease by the technique of PCR.

Authors:  Praneeta J Singh; A C Shrivastava; A V Shrikhande
Journal:  Indian J Hematol Blood Transfus       Date:  2014-07-08       Impact factor: 0.900

2.  Nationwide survey for current clinical status of amniocentesis and maternal serum marker test in Japan.

Authors:  Hidehiko Miyake; Shigehito Yamada; Yosuke Fujii; Hideaki Sawai; Naoko Arimori; Yasuko Yamanouchi; Yuka Ozasa; Makoto Kanai; Haruhiko Sago; Akihiko Sekizawa; Fumio Takada; Hideaki Masuzaki; Yoichi Matsubara; Fumiki Hirahara; Koji Kugu
Journal:  J Hum Genet       Date:  2016-06-30       Impact factor: 3.172

3.  Non-invasive prenatal testing in mitigating concerns from invasive prenatal diagnostic testing: retrospective assessment of utility in an academic healthcare system in the US.

Authors:  Kibum Kim; Linda Kaitlyn Craft
Journal:  BMJ Open       Date:  2022-06-15       Impact factor: 3.006

4.  NSGC practice guideline: prenatal screening and diagnostic testing options for chromosome aneuploidy.

Authors:  K L Wilson; J L Czerwinski; J M Hoskovec; S J Noblin; C M Sullivan; A Harbison; M W Campion; K Devary; P Devers; C N Singletary
Journal:  J Genet Couns       Date:  2012-11-22       Impact factor: 2.537

5.  Maternal serologic screening to prevent congenital toxoplasmosis: a decision-analytic economic model.

Authors:  Eileen Stillwaggon; Christopher S Carrier; Mari Sautter; Rima McLeod
Journal:  PLoS Negl Trop Dis       Date:  2011-09-27

6.  An economic analysis of chromosome testing in couples with children who have structural chromosome abnormalities.

Authors:  Kittiphong Thiboonboon; Wantanee Kulpeng; Yot Teerawattananon
Journal:  PLoS One       Date:  2018-06-19       Impact factor: 3.240

7.  Microbiome profile of the amniotic fluid as a predictive biomarker of perinatal outcome.

Authors:  Daichi Urushiyama; Wataru Suda; Eriko Ohnishi; Ryota Araki; Chihiro Kiyoshima; Masamitsu Kurakazu; Ayako Sanui; Fusanori Yotsumoto; Masaharu Murata; Kazuki Nabeshima; Shin'ichiro Yasunaga; Shigeru Saito; Makoto Nomiyama; Masahira Hattori; Shingo Miyamoto; Kenichiro Hata
Journal:  Sci Rep       Date:  2017-09-22       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.